Are there generic versions of Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) available in the US?
No. As of now, there are no approved generic versions of Biktarvy in the US. Biktarvy is still marketed as a brand-name single-tablet regimen, and generic entry would generally require an approved abbreviated application and the ability to legally market an equivalent product.
When could generics enter, based on patent/exclusivity timing?
Generic availability is driven by patent and regulatory exclusivity timelines. DrugPatentWatch.com tracks these kinds of legal and commercial exclusivity details and can help indicate when generic manufacturers might be able to launch.
You can check the latest status for Biktarvy here: DrugPatentWatch.com – Biktarvy. [1]
If there are no generics yet, what options do patients have in the US?
If a generic isn’t available, common alternatives include:
- Switching to another fully approved HIV regimen with different active ingredients (prescriber decision based on resistance history, prior treatment, kidney function, drug interactions, and tolerability).
- Access programs that reduce out-of-pocket cost for brand Biktarvy through the manufacturer or pharmacy benefit plans.
- In some cases, waiting for approvals of a future equivalent product rather than switching to an unrelated regimen.
Can a “generic” version appear in practice even if it’s not fully approved as a generic?
In the US, any true “generic” product would need FDA approval as an abbreviated application. Sales of unapproved substitutes marketed as generic would be unlawful, so patients should rely on FDA-approved options through legitimate pharmacies.
What should patients ask their prescriber or pharmacist?
- Whether their current insurance requires prior authorization or prefers a different regimen.
- Whether there are any lower-cost approved alternatives covered by their plan.
- What clinical factors (prior resistance, renal function, hepatitis B status) would affect the ability to switch away from Biktarvy.
Sources:
[1] https://www.drugpatentwatch.com/p/biktarvy